Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer
Status:
Recruiting
Trial end date:
2024-09-10
Target enrollment:
Participant gender:
Summary
This phase II trial studies the effect of selpercatinib given before surgery in treating
patients with thyroid cancer whose tumors have RET alterations (changes in the genetic
material [deoxyribonucleic acid (DNA)]). Selpercatinib may stop the growth of tumor cells by
blocking some of the enzymes needed for cell growth. Giving selpercatinib before surgery may
help shrink the tumors and help control the disease.